Cargando…

Systemic therapy augmented by radiotherapy (STAR) effect for brain metastases in a BRAF-mutated melanoma patient with prolonged survival: a case report

Brain metastases are common in stage IV malignant melanoma, carrying a prognosis traditionally regarded as severe, with a median survival of few months. Recently introduced systemic therapies as targeted therapy or immunotherapy have significantly improved the prognosis of metastatic melanoma. The o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cristaudo, Agostino, Malorgio, Antonio, Medoro, Serena, Stefanelli, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society for Radiation Oncology 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024180/ https://www.ncbi.nlm.nih.gov/pubmed/33794577 http://dx.doi.org/10.3857/roj.2020.00724

Ejemplares similares

Targeted Therapy After Brain Radiotherapy for BRAF-Mutated Melanoma With Extensive Ependymal Disease With Prolonged Survival: Case Report and Review of the Literature
por: Abu-Gheida, Ibrahim, et al.
Publicado: (2019)

Squamous cell carcinoma (SCC) of the Pyriform sinus with multiple metachronous brain metastases, a case report
por: Cristaudo, Agostino, et al.
Publicado: (2020)

BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy
por: Chowdhary, Mudit, et al.
Publicado: (2016)

Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma
por: Jain, Tania, et al.
Publicado: (2015)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

THER-10. IMPACT OF BRAF MUTATIONAL STATUS ON THE EFFICACY OF IMMUNOTHERAPY FOR MELANOMA BRAIN METASTASES
por: Lauko, Adam, et al.
Publicado: (2019)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

Dabrafenib and Trametinib prolong coagulation through the inhibition of tissue factor in BRAF(v600e) mutated melanoma cells in vitro
por: Scatena, Cristian, et al.
Publicado: (2019)

BRAF Mutation Heterogeneity in Melanoma Lesions
por: SAKAIZAWA, Kaori, et al.
Publicado: (2020)

Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma
por: Satzger, Imke, et al.
Publicado: (2015)

Neoadjuvant radiotherapy dose escalation for locally advanced rectal cancers in the new era of radiotherapy: A review of literature
por: Delishaj, Durim, et al.
Publicado: (2021)

The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy
por: Hannan, Enda J., et al.
Publicado: (2017)

BRAF Mutation Is Associated with Improved Local Control of Melanoma Brain Metastases Treated with Gamma Knife Radiosurgery
por: Gallaher, Ian S., et al.
Publicado: (2016)

Radiotherapy cannot prolong overall survival of young prostate cancer patients with bone metastases
por: Peng, Bo, et al.
Publicado: (2016)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2023)

Clinical significance of BRAF mutations in metastatic melanoma
por: Chang, David Z, et al.
Publicado: (2004)

Development of encorafenib for BRAF-mutated advanced melanoma
por: Koelblinger, Peter, et al.
Publicado: (2018)

Atypical BRAF and NRAS Mutations in Mucosal Melanoma
por: Dumaz, Nicolas, et al.
Publicado: (2019)

Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors
por: Dolinsek, Tanja, et al.
Publicado: (2016)

Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report
por: Kim, Dae Won, et al.
Publicado: (2015)

Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma()()
por: Kim, Hee Kyung, et al.
Publicado: (2016)

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
por: Gonzalez-Cao, Maria, et al.
Publicado: (2021)

Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas
por: Edmunds, S C, et al.
Publicado: (2003)

Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition
por: Hardeman, Keisha N., et al.
Publicado: (2017)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
por: Reinhard, Raphael, et al.
Publicado: (2018)

Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases
por: PELLEGRINI, Cristina, et al.
Publicado: (2020)

BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal Melanomas
por: Colombino, Maria, et al.
Publicado: (2019)

Survival According to BRAF-V600 Tumor Mutations – An Analysis of 437 Patients with Primary Melanoma
por: Meckbach, Diana, et al.
Publicado: (2014)

BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases
por: Fakhruddin, Najla, et al.
Publicado: (2017)

Frequency of BRAF Mutation and Clinical Relevance for Primary Melanomas
por: Lee, Hyoun Wook, et al.
Publicado: (2012)

Current State of Target Treatment in BRAF Mutated Melanoma
por: Tanda, Enrica Teresa, et al.
Publicado: (2020)

The Relevance of Assessing Subjective Experiences of Skin Toxicity During Adjuvant Radiotherapy for Breast Cancer
por: Bottesi, Gioia, et al.
Publicado: (2021)

Utilization of Reactive Oxygen Species Targeted Therapy to Prolong the Efficacy of BRAF Inhibitors in Melanoma
por: Yuan, Long, et al.
Publicado: (2018)

Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations
por: Heinzerling, L, et al.
Publicado: (2013)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
por: Colombino, Maria, et al.
Publicado: (2013)

Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients
por: Herbreteau, Guillaume, et al.
Publicado: (2020)

An integrated disease-specific graded prognostic assessment scale for melanoma: contributions of KPS, CITV, number of metastases, and BRAF mutation status
por: Ahluwalia, Manmeet, et al.
Publicado: (2020)

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
por: Manca, Antonella, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0i1qbcp6o3hk8h1nfkhlcnnb6e